Skip to content

Author

A. Kasiakogias

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Risk stratification in early non-ischaemic cardiomyopathy: the interplay of genetics and cardiac imaging

Preventing sudden cardiac death (SCD) in early non-ischaemic cardiomyopathy (NICM) remains a major clinical challenge. Traditional risk stratification centred on left ventricular ejection fraction (LVEF) poorly captures arrhythmic risk, particularly in early dilated cardiomyopathy (DCM) and non-dilated left ventricular...

A. Kasiakogias, C. Antoniou, T. Tsampras et al. · 0 citations
Open access Oct 2026

The effect of eplerenone vs irbesartan as first line therapy in obese hypertensive patients on left ventricular hypertrophy and diastolic dysfunction: echocardiographic results of the HEBRO randomized

The pathophysiology of hypertension in obese patients is complex and multifactorial. Obesity is significantly associated with adverse cardiovascular outcomes. The relationship between obesity and hypertension is well described. However, little is known about the impact of aldosterone blockade using eplerenone in...

M. Kouremeti, P. Iliakis, S. Drogkaris et al. · 0 citations
Open access Oct 2026

Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial

The pathophysiology of hypertension in obese patients is complex and multifactorial. Obesity is significantly associated with adverse cardiovascular outcomes. The relationship between obesity and hypertension is well described. However, little is known about the impact of aldosterone blockade using eplerenone in...

P. Iliakis, M. Kouremeti, S. Drogkaris et al. · 0 citations
Open access Oct 2026

Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial

In obese hypertensive patients, first-line treatment with eplerenone was not associated with excess renal function decline or clinically significant hyperkalemia compared with irbesartan, and these findings support the renal safety of MRA-based first-line therapy in this population.

P. Iliakis, M. Kouremeti, S. Drogkaris et al. · 0 citations
Open access Oct 2026

Long-term effects of renal denervation on hypertension management: insights from a center of excellence

Renal denervation (RDN) has been approved in recent guidelines as the third pillar for the management of resistant or uncontrolled hypertension. The aim of this study was to evaluate the long-term outcomes of radiofrequency (RF) RDN in a cohort of patients treated at an ESH center of excellence, with a mea...

K. Kyriakoulis, S. Soulaidopoulos, D. Konstantinidis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.